NCT/Study#
NCT03126916 /
COG-ANBL1531
A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL) (IND# 134379)
DISEASE GROUP:
Pediatric Oncology
current phase:
Phase III
STUDY STATUS:
Enrolling
Location:
Hackensack, NJ
For More information:
